- Products & Services
- Knowledge Base
OREM, UT, March 12, 2013 /24-7PressRelease/ -- Forty-three of 44 providers interviewed by KLAS said they would buy tomosynthesis again despite the additional time it takes and the unpredictable reimbursement. This and other findings are available in the new KLAS report Breast Tomosynthesis 2013: The Business Case.
Providers leveraging the tomosynthesis technology experience increased time and costs associated with image storage, yet providers told KLAS the benefits outweigh the costs, and they are reaping the benefits of this emerging technology.
"This is a really exciting technology to watch evolve," said Monique Rasband, research director and report author. "In our 2012 report on women's imaging, we received an overwhelming response from providers to dive deeper into the clinical and financial impact of tomosynthesis. And what we have uncovered in this 2013 study will really help those who are considering tomosynthesis as a move-forward option. "
Although Hologic is the only FDA-approved vendor for tomosynthesis, many other vendors, including GE, Giotto, Philips, Planmed, and Siemens, are making progress toward tomosynthesis. To learn more about the breast tomosynthesis vendors and findings in this study, check out the full report, Breast Tomosynthesis 2013: The Business Case. This report is available to healthcare providers at a significant discount. To purchase, visit www.KLASresearch.com/KLASreports.
KLAS is a research firm on a global mission to improve healthcare delivery by enabling providers to be heard and to be counted. Working with thousands of healthcare executives and clinicians, KLAS gathers data on software, services, medical equipment, and infrastructure systems to deliver timely reports, trends, and statistical overviews. The research directly represents the provider voice and acts as a catalyst for improving vendor performance. KLAS was founded in 1996, and KLAS' staff and advisory board members average 25 years of healthcare information technology experience. For more information, go to www.KLASresearch.com, email marketing@KLASresearch.com, or call 1-800-920-4109 to speak with a KLAS representative. Follow KLAS on Twitter https://twitter.com/klasresearch.
# # #